We are hiring a Chief Executive Officer for Truffle Capital’s portfolio company, Diaccurate. Truffle Capital raised €250M for its BioMedTech Startup Fund with the purpose of creating a portfolio of MedTech startups from scratch and incubating them long enough to raise external capital or be positioned to exit.
Successful Truffle Capital Exits:
We have partnered with Alain Chevallier, Senior Partner of BioMedTech, to hire our CEO of Diaccurate to facilitate its Phase III clinical development. This position will operate as the strategic leader to drive the regulatory, market access, and clinical trial pathways while positioning Diaccurate for future commercial success in the United States.
**Required experience includes leading Phass III oncology through clinical development and experience working in a publicly traded company**
Develop and implement strategic plans for the company, including the development of the drug portfolio, market access, business combination, and funding strategies
Oversee all research and development efforts, including conducting a Phase 3 clinical trial in metastatic breast cancer and the development of a portfolio of new oncology treatments in various cancer indications
Lead fundraising efforts to secure the necessary capital to support the company’s growth plans via equity and non-dilutive sources of capital
Lead the company to a successful IPO on a major stock exchange (NASDAQ and/or EURONEXT) to raise capital and provide liquidity to the shareholders
Build and lead a world-class organization to implement the strategy
Lead the effort to establish strategic partnerships with Pharma/Biotech companies that may be interested in the company’s oncology assets
Build strong relationships with investors, analysts, the scientific community, and key opinion leaders in oncology
Shape the culture and values of the company, setting high standards for performance, accountability, and ethics
Bachelor’s degree required, Master’s Degree/MBA preferred
Endocrine-resistant metastatic breast tumor, glioblastoma, refractory acute myeloid leukemia, … to beat incurable cancers, Diaccurate explores the new frontiers of oncology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing 3 proprietary therapeutics with novel mechanisms of action across several development programs:
– DIACC3010, an optimized S6 Kinase inhibitor, highly selective oral antitumoral agent that crosses the blood-brain barrier
– DIACC2010, a sole-in-class KIF20A kinesin inhibitor, a novel oncology target, IV antitumoral agent with high selectivity towards cancer cells
-DIACC2020, antibody drug conjugate using DIACC2010 as payload.
Co-founded by Truffle Capital, Diaccurate has forged alliances with leaders in academia and industry, including Pasteur Institute, Paoli-Calmettes Institute (Marseille, France) and now Merck KGaA (Darmstadt, Germany). It relies on a high-level management team led by Dominique Bridon, PhD and a world-class Scientific Advisory Board chaired by Prof. Tasuku Honjo, recipient of the 2018 Nobel Prize in Medicine.
Chairman of the Board
Co-Founder of Truffle Capital
Operating Partner at Truffle Capital
Senior Partner at Truffle Capital
Lifeblood™ supports global MedTech Startups with Talent Acquisition and Fundraising Strategies. We build full-scale startup teams from Board and C-level executives to entry-level individual contributors and from early-stage R&D through multi-national commercialization phases.Approaching two decades of experience in the MedTech industry, our talent acquisition services and team-building efforts are the results of 2,000+ successful hires for 500+ companies in 6 continents. We have facilitated more than $220 million for MedTech startups with our fundraising strategies and global investor network.
People and money are the lifeblood capital of startups. Learn from our entrepreneurs and investors as we demystify raising and investing capital on our MedTech Money Podcast Series.